Swissmedic publishes Information concerning an official Warning from Brazil regarding Falsified Medicinal Product
Recommendation
6/7 May 2026
Copenhagen, Denmark
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Swissmedic has been informed by the Brazilian Health Regulatory Agency ANVISA that Brazil has suspended all imports of medicinal products from three Turkish wholesalers. The reason for this is the export of falsified units from Turkey to Brazil. One of the batches was also obtained from Turkey and sold to Brazil by a Swiss wholesaler.
In this regard, an information for Swiss companies was published. The Swissmedic points out that Swiss companies are also not permitted to supply medications obtained from the Turkish wholesalers to Brazil.
The names of the three wholesalers and further information can be found on the website of Swissmedic.
Related GMP News
21.04.2026Implementation of GDP for Pharmaceutical Products in Hong Kong
21.04.2026China's NMPA: Guiding Opinions & Q&A on Standardising Modern Pharmaceutical Logistics
21.04.2026GMDP IWG Three-Year Work Plan: What's Planned for GDP?
21.04.2026Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 2
25.03.2026What is Good Distribution Practice (GDP)?
24.03.2026What Requirements must a Responsible Person for GDP meet?